Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Industry, Sector and Symbol
Stock Exchange TSE
Industry Technical & System Software
Sub-IndustryN/A
SectorComputer and Technology
SymbolTSE:AUP
CUSIPN/A
Phone+1-250-7084272
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-45,241.38%
Return on Equity-30.41%
Return on Assets-25.82%
Miscellaneous
EmployeesN/A
Outstanding Shares84,200,000
Market CapC$596.22
Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."
How were Aurinia Pharmaceuticals' earnings last quarter?
Aurinia Pharmaceuticals Inc (TSE:AUP) posted its quarterly earnings data on Thursday, May, 10th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.07 million. Aurinia Pharmaceuticals had a negative return on equity of 30.41% and a negative net margin of 45,241.38%. View Aurinia Pharmaceuticals' Earnings History.
When is Aurinia Pharmaceuticals' next earnings date?
What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include Iress (IRE), Computer Modelling Group (CMG), GB Group (GBG), Emis Group (EMIS), Wandisco (WAND), SDL (SDL), Microgen (MCGN), Absolute Software (ABT), Dotdigital Group (DOTD), TECSYS (TCS), Ideagen (IDEA), iSentia Group (ISD), Smart Parking (SPZ), IDOX (IDOX) and Gresham Technologies (GHT).
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 60)
- Mr. Michael R. Martin, Co-Founder & COO
- Mr. Dennis Bourgeault C.A., CFO & Sec.
- Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
- Dr. Neil Solomons M.D., Chief Medical Officer
Has Aurinia Pharmaceuticals been receiving favorable news coverage?
News coverage about AUP stock has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a daily sentiment score of 0.02 on Accern's scale. They also assigned media stories about the company an impact score of 46.63 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Aurinia Pharmaceuticals?
Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Aurinia Pharmaceuticals' stock price today?
One share of AUP stock can currently be purchased for approximately C$7.47.
How big of a company is Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals has a market capitalization of C$596.22 million.
How can I contact Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.
MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days.
